VRDNHealthcare · BiotechnologyThe 17 Wall Street analysts covering Viridian Therapeutics, Inc. hold a median 12-month price target of $35 — +20.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 4 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Viridian Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (92): Analysts have, on balance, been raising their forecasts.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on VRDN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +20.5% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Nov 2026 | Needham | Maintains | Buy | $34 → $38 |
| 22 Sept 2026 | RBC Capital | Maintains | Outperform | $36 → $38 |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $35 → $36 |
| 7 Aug 2026 | Truist Securities | Maintains | Buy | $38 → $39 |
| 7 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 30 June 2026 | Needham | Maintains | Buy | — |
| 30 June 2026 | Needham | Maintains | Buy | $32 → $34 |
| 30 June 2026 | RBC Capital | Maintains | Outperform | $34 → $35 |
| 30 June 2026 | RBC Capital | Maintains | Outperform | — |
| 30 June 2026 | Truist Securities | Maintains | Buy | $35 → $38 |
| 30 June 2026 | Truist Securities | Maintains | Buy | — |
| 30 June 2026 | Wedbush | Maintains | Outperform | — |
| 30 June 2026 | Wedbush | Maintains | Outperform | $32 → $43 |
| 29 June 2026 | Needham | Reiterates | Buy | — |
| 29 June 2026 | Needham | Reiterates | Buy | $32 |
| 29 June 2026 | Wells Fargo | Upgrade | Overweight | $20 → $31 |
| 29 June 2026 | Wells Fargo | Upgrade | Overweight | — |
| 15 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 May 2026 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VRDN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Viridian Therapeutics, Inc. returned +28.8% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 5% of US stocks
Cheaper than 19% of US stocks
Cheaper than 81% of US stocks
Higher than 96% of US stocks
Higher than 92% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 18% of US stocks
Higher than 14% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Viridian Therapeutics, Inc. has a market value of $3.3B and an enterprise value of $2.2B.
Revenue in the twelve months to 30 June 2026: $71.1M. The latest quarter grew 278.7% year on year.
Net income over the same four quarters: −$387.0M, a −544.1% net margin.
Diluted earnings per share, trailing twelve months: $−3.37.
Free cash flow in the twelve months to 30 June 2026: −$335.0M.
Trailing P/E: −8.7×; forward P/E: −10.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Viridian Therapeutics, Inc. employs 252 people — $282K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Viridian Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Viridian Therapeutics reported $24.7 million in Lumvoa net product revenue in the treatment’s first quarter on the market. More than 100 patients had received at least one infusion by Sept. 30.
Why it matters — The figures provide an early view of Lumvoa’s commercial uptake for VRDN watchers.
Seeking Alpha published the transcript of Viridian Therapeutics’ Q3 2026 earnings call. The provided text contains no further details from the call.
Why it matters — The transcript is a source for VRDN watchers seeking the company’s Q3 2026 call discussion; no specific topics or results are described in the excerpt.
Viridian Therapeutics reported a third-quarter loss of $0.81 per share, compared with the consensus estimate of a $1.01 loss. The loss was $0.34 per share in the year-earlier quarter.
Why it matters — VRDN watchers may note that the reported quarterly loss was smaller than analysts’ estimate, while still exceeding the year-ago loss.
Viridian Therapeutics reported third-quarter 2026 financial results and business updates for the period ended September 30, 2026. CEO Steve Mahoney said the early launch of Lumvoa in TED had exceeded expectations.
Why it matters — The update offers VRDN watchers information on the company’s quarterly results and its reported early launch performance for Lumvoa in TED.
Viridian Therapeutics said it will report third-quarter 2026 financial results before the market opens on November 4, 2026. Management will host a conference call at 8:00 a.m. ET that day to discuss the results and provide a business update.
Why it matters — VRDN watchers can look to the scheduled release and call for the company’s financial results and business update.
The 17 Wall Street analysts covering Viridian Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $22 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Viridian Therapeutics, Inc., 17 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Viridian Therapeutics, Inc. 55 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Viridian Therapeutics, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +20.5% from the last close, and Ticker Nerd's factor model ranks Viridian Therapeutics, Inc. 55 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Viridian Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRDN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $50 over the next 12 months.
Viridian Therapeutics, Inc. returned +28.8% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Viridian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and rare diseases, with a primary emphasis on thyroid eye disease.
The most recent item we track (MarketBeat, 4 Nov 2026): "What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call". Viridian Therapeutics reported $24.7 million in Lumvoa net product revenue in the treatment’s first quarter on the market. More than 100 patients had received at least one infusion by Sept. 30.
Viridian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and rare diseases, with a primary emphasis on thyroid eye disease. The company’s current pipeline centers on antibody-based programs designed to target validated disease pathways, including intravenous and subcutaneous candidates for thyroid eye disease and additional assets aimed at autoimmune conditions. Viridian Therapeutics also advances FcRn inhibitor programs, expanding its work across immunology-focused indications. The company operates in the biotechnology and specialty therapeutics market, where it contributes to the development of differentiated medicines for patients with serious conditions that have limited treatment options. Headquartered in Waltham, Massachusetts, Viridian Therapeutics combines antibody discovery and protein engineering to support its research, clinical development, and future commercialization efforts.
CEO Mr. Stephen F. Mahoney J.D., MBA · 252 employees · United States · https://www.viridiantherapeutics.com
